Ike­na On­col­o­gy drops an ear­ly-stage pro­gram as it looks to stretch its cash

An­oth­er biotech is lin­ing up to cut a piece of its pipeline to ex­tend its cash­flow. The Boston-based, can­cer-cen­tered biotech Ike­na On­col­o­gy is look­ing to make some changes to its pipeline, in­clud­ing a cull of one of its ear­ly-stage pro­grams.

Ike­na an­nounced this week that af­ter con­duct­ing a “port­fo­lio re­view,” it will dis­con­tin­ue the in­ter­nal clin­i­cal de­vel­op­ment of its can­di­date IK-007, an EP4 an­tag­o­nist, and that it is “ex­plor­ing strate­gic al­ter­na­tives” for the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER